Login to Your Account



Zealand Pharma Gets $11M Milestone from Deal

Abbott Acquires Action's AKI Compound for $110M in Cash

By Marie Powers
Staff Writer

Friday, May 4, 2012
Pharma giant Abbott plunked down $110 million in cash to acquire AP214, a first-in-class alpha-MSH peptide derivative designed to prevent acute kidney injury (AKI) during major cardiac surgery in patients at increased risk, from privately held Action Pharma A/S, of Aarhus, Denmark.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription